Get the Stockscreener App
27.16
1.31%
0.35
After Hours:
27.05
-0.11
-0.41%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.16, with a volume of 42.76M.
It is up +1.31% in the last 24 hours and down -1.63% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.81
Open:
$26.82
24h Volume:
42.76M
Relative Volume:
0.91
Market Cap:
$154.44B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
20.04
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
+2.18%
1M Performance:
-1.63%
6M Performance:
+10.54%
1Y Performance:
+1.95%
1-Day Range:
$26.52
$27.29
1-Week Range:
$26.20
$27.29
52-Week Range:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.16 | 152.45B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,001.35 | 900.48B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.71 | 584.62B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.01 | 402.17B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.59 | 310.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.99 | 302.33B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Yahoo Finance
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Pfizer’s tilrekimig meets Phase 2 trial endpoint for dermatitis - Investing.com India
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
Anti Infective Vaccines Market Witnessing Massive Growth - openPR.com
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Where Will Eli Lilly Stock Be in 10 Years? - The Motley Fool
Is Pfizer Inc. stock gaining market share2025 Bull vs Bear & Community Consensus Trade Signals - Naître et grandir
American Century Companies Inc. Sells 546,598 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Obesity Nod In China And Cancer Wins Reframe Long Term Growth - Yahoo Finance
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN - AASTOCKS.com
China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders
Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg
China approves Pfizer GLP-1 drug for weight management - Yahoo Finance
China approves Pfizer GLP-1 drug for weight loss - Reuters
Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters
Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS
Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate - Yahoo Finance
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Retinal Vein Occlusion Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer - Barchart.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - TradingView
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.66%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):